INTRODUCTION: The risk of breast cancer recurrence has been linked to tumour size, grade, oestrogen (ER) receptor status, and degree of lymph node (LN) involvement. However, the role of these variables in predicting time to relapse is not well defined. This study was designed to identify patient and primary tumour characteristics that predict risk periods for breast cancer recurrence within our institution, to enable more tailored surveillance strategies. METHODS: We retrospectively studied a cohort of 473 patients who presented to The Queen Elizabeth Hospital, Adelaide, Australia, with recurrent breast cancer between 1968 and 2008. Patient and primary tumour characteristics were collected, including age, menopausal status, tumour grade, size, ER and progesterone receptor (PR) status, and LN involvement and modeled against time to relapse using Kaplan-Meier survival curves. RESULTS: High tumour grade, size ≥ 20 mm, ER negativity, and PR negativity were shown on univariate analysis to correlate significantly with earlier recurrence (P < 0.0001, P = 0.0012, P = 0.0006, and P = 0.006). Multivariate analysis identified tumour grade and size as significant predictors of timing of relapse after adjustment for other variables. LN involvement, menopausal status, and age did not significantly correlate with earlier recurrence. CONCLUSIONS: High tumour grade and larger size were shown to independently predict earlier breast cancer relapse. While LN involvement increases absolute recurrence risk, our study proposes that it does not influence timing of relapse. Use of these predictors will enable key risk periods for onset of relapse to be characterised according to tumour profile with more appropriate discharge to primary care providers for ongoing surveillance.
INTRODUCTION: The risk of breast cancer recurrence has been linked to tumour size, grade, oestrogen (ER) receptor status, and degree of lymph node (LN) involvement. However, the role of these variables in predicting time to relapse is not well defined. This study was designed to identify patient and primary tumour characteristics that predict risk periods for breast cancer recurrence within our institution, to enable more tailored surveillance strategies. METHODS: We retrospectively studied a cohort of 473 patients who presented to The Queen Elizabeth Hospital, Adelaide, Australia, with recurrent breast cancer between 1968 and 2008. Patient and primary tumour characteristics were collected, including age, menopausal status, tumour grade, size, ER and progesterone receptor (PR) status, and LN involvement and modeled against time to relapse using Kaplan-Meier survival curves. RESULTS:High tumour grade, size ≥ 20 mm, ER negativity, and PR negativity were shown on univariate analysis to correlate significantly with earlier recurrence (P < 0.0001, P = 0.0012, P = 0.0006, and P = 0.006). Multivariate analysis identified tumour grade and size as significant predictors of timing of relapse after adjustment for other variables. LN involvement, menopausal status, and age did not significantly correlate with earlier recurrence. CONCLUSIONS:High tumour grade and larger size were shown to independently predict earlier breast cancer relapse. While LN involvement increases absolute recurrence risk, our study proposes that it does not influence timing of relapse. Use of these predictors will enable key risk periods for onset of relapse to be characterised according to tumour profile with more appropriate discharge to primary care providers for ongoing surveillance.
Authors: A Neri; D Marrelli; S Rossi; A De Stefano; F Mariani; G De Marco; S Caruso; G Corso; T Cioppa; E Pinto; F Roviello Journal: World J Surg Date: 2007-01 Impact factor: 3.352
Authors: A Wallgren; M Bonetti; R D Gelber; A Goldhirsch; M Castiglione-Gertsch; S B Holmberg; J Lindtner; B Thürlimann; M Fey; I D Werner; J F Forbes; K Price; A S Coates; J Collins Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: L Mauriac; A Keshaviah; M Debled; H Mouridsen; J F Forbes; B Thürlimann; R Paridaens; A Monnier; I Láng; A Wardley; J-M Nogaret; R D Gelber; M Castiglione-Gertsch; K N Price; A S Coates; I Smith; G Viale; M Rabaglio; N Zabaznyi; A Goldhirsch Journal: Ann Oncol Date: 2007-02-14 Impact factor: 32.976
Authors: J E Panoff; J Hurley; C Takita; I M Reis; W Zhao; V Sujoy; C R Gomez; M Jorda; L Koniaris; J L Wright Journal: Breast Cancer Res Treat Date: 2011-04-08 Impact factor: 4.872
Authors: Abenaa M Brewster; Gabriel N Hortobagyi; Kristine R Broglio; Shu-Wan Kau; Cesar A Santa-Maria; Banu Arun; Aman U Buzdar; Daniel J Booser; Vincente Valero; Melissa Bondy; Francisco J Esteva Journal: J Natl Cancer Inst Date: 2008-08-11 Impact factor: 13.506
Authors: Olivia Pagani; Karen N Price; Richard D Gelber; Monica Castiglione-Gertsch; Stig B Holmberg; Jurij Lindtner; Beat Thürlimann; John Collins; Martin F Fey; Alan S Coates; Aron Goldhirsch Journal: Breast Cancer Res Treat Date: 2009-01-10 Impact factor: 4.872
Authors: James Mansell; Ian J Monypenny; Anthony I Skene; Paul Abram; Robert Carpenter; Jennifer M Gattuso; Christopher R Wilson; Wilson J Angerson; Julie C Doughty Journal: Breast Cancer Res Treat Date: 2008-12-27 Impact factor: 4.872
Authors: Margherita Boieri; Anna Malishkevich; Ranya Guennoun; Emanuela Marchese; Sanne Kroon; Kathryn E Trerice; Mary Awad; Jong Ho Park; Sowmya Iyer; Johannes Kreuzer; Wilhelm Haas; Miguel N Rivera; Shadmehr Demehri Journal: J Exp Med Date: 2022-06-03 Impact factor: 17.579
Authors: Michael S Shawky; Hilary Martin; Honor J Hugo; Thomas Lloyd; Kara L Britt; Andrew Redfern; Erik W Thompson Journal: Oncotarget Date: 2017-01-17